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Supramolecular Pd2L4 cages (L = ligand) hold promise as drug delivery systems. With the idea of achieving targeted delivery 
of the metallacages to tumor cells, the bioconjugation of exo-functionalized self-assembled Pd2L 4 cages to peptides 
following two different approaches is reported for the first time. The obtained bioconjugates were analyzed and identified 
by high-resolution mass spectrometry. 
 
Chemotherapy is one of the main modalities of treatment for cancer patients. However, its success rate remains limited, 
primarily due to limited selectivity of drugs for the tumor tissue, often resulting in severe toxicity, as well as to the development 
of multi-drug resistance caused by the heterogeneous biology of the growing tumors. 
 
In general, an important challenge in cancer treatment is to find a technology for targeted delivery and controlled release of 
drugs to eradicate tumor cells while sparing normal ones. Therefore, considerable efforts have been devoted to the 
development of drug delivery systems that can overcome the above mentioned issues related to anticancer drugs used in 
chemotherapy.1, 2 In some cases, it was also possible to achieve a synergistic anticancer effect of different therapeutic 
modalities combined in one drug delivery system.3 Within this framework, an increasing number of reports has appeared on 
tethering anticancer compounds to or encapsulating them in a wide range of functional molecules or nanomaterials with or 
without targeting groups.4-6 Thus, lipid nano-systems, such as liposomes and micelles along with virus-inspired vectors and 
polymeric particles, as well as inorganic nanoparticles, have been studied to deliver bioactive compounds to the target tissues. 
 
In this context, supramolecular chemistry offers new opportunities for improved drug delivery systems, its principal aim 
being to create nanoscale structures while exerting control over their size and shape, and to emulate biological systems with 
synthetic ones.7 
 
Interestingly, coordination-driven self-assembly utilizes the spontaneous formation of metal-ligand bonds in solution to 
drive mixtures of molecular building blocks to single, unique 2D metallocycles or 3D metallacages based on the directionality of 
the precursors used. The supramolecular coordination complexes (SCCs) obtained via this process are characterized by well-
defined internal cavities and relatively facile pre- or post-self-assembly functionalization.8 These properties augment the 
modularity of the directional bonding design strategy to provide structures with unprecedented fine-tuning possibilities, 
spatially and electronically. In spite of the numerous advantages of SCCs, these systems have been the least-explored of the 
supramolecular material categories for biomedical applications, both as drug delivery systems and as anticancer agents. 
 
A specific and attractive area of SCCs is the self-assembly of M2L4 (M =metal, L = ligand) metallacages,9 which can enclose a 
wide range of small molecules within their cavity, such as ions 10-14  and neutral molecules. 15-21 In addition, the properties of the 
M2L4 coordination cages can be optimized by functionalization of the ligand framework with the aim to target molecular system 
to a specific cell/tissue type or to enhance detection. Recently, we investigated fluorescent Pd2L4 cages (with L being exo-
functionalized bipyridyl ligands) as drug delivery systems for cisplatin, which proved to be active in cancer cells, while showing 
low ex vivo toxicity in healthy rat liver tissue.15 The obtained Pd(II) metallacages showed fluorescence properties due to the 
used ligand system. Similarly, exo-functionalized cages with naphthalene or anthracene groups, or featuring Ru (II) pyridine 
complexes, were studied with the aim to image their fate in cells via fluorescence microscopy.22, 23 
 
Selective accumulation of metallacages in tumors has been hypothesized to occur via the enhanced permeability and 
retention (EPR) effect,24 which has been widely used in cancer therapy for delivery via passive targeting. In fact, the EPR effect 
has been predominantly shown to be involved in the passive targeting of drugs with a molecular weight of more than 40 kDa 
and for low molecular weight drugs presented in drug-carriers such as polymeric conjugates, liposomes, polymeric 
nanoparticles, and micellar systems to solid tumors.25 However, for supramolecular metallacages, with molecular weight of ca. 
2-3 KDa, the EPR effect is not likely to influence their delivery. Therefore, it can be assumed that successful conjugation of cell-
specific ligands to the cage, including tumor-targeting peptides (TTPs) that are specific for tumor related surface markers, such 
as membrane receptors,4, 26could improve target specificity and efficacy. However, so far this concept has never been 
explored, and only Fujita et al. have been published on the non-covalent peptide coating on self-assembled M12L24 
coordination spheres.27 
 
The synthesis of three Pd2L4 cages and their bioconjugation to a model peptide is reported in this work. To the best of our 
knowledge this is the first attempt to bioconjugate M2L 4 cages to peptides. The selected cages feature COOH or NH2 groups in 
exo position for coupling to the peptide by amide bond formation (Fig. 1, C1a, C1b, C1c). It is also investigated whether a longer 
aliphatic linker between the COOH group and the cage favours coupling of the targeting moiety by reducing possible steric 
hindrance. 
 
It is worth mentioning that we have opted for this classical bioconjugation method instead of the modern click-chemistry 
approach, since the latter may lead to interference of Cu2+ ions with the stability of the self-assembled cage. In fact, click 
chemistry makes often use of copper in the concentration range 50-250 µM or higher,28 which would be ca. equivalent to the 
necessary concentration of Pd2+ precursor and resulting metallacage, therefore, leading to possible ligand exchange reactions. 
 
The bioconjugation was performed using two different approaches: i) direct tethering of the metallacage to the peptide 
(Approach I); or ii) initial anchoring of the ligand to the peptide, followed by metallacage self-assembly (Approach II) (Fig. 1). 
Formation of the metallacage-peptide constructs was assessed via high-resolution electrospray mass spectrometry in most 
cases coupled to high performance liquid chromatography (LC-MS). The obtained results are discussed in relation to the 
advantages and disadvantages of the reported bioconjugation approaches, and constitute the proof of concept for further 
studies using peptides selected for targeting properties (e.g. cyclic RGD peptides or affimers). 
 
Synthesis 
The rigid bidentatepyridyl ligands L1a-L3a (see Fig. 1) were synthesized using Sonogashira cross-coupling. Reaction of the 
ligands L1a-L3a with the Pd precursor [Pd(NCCH3)4](BF4)2 in a 2:1 ratio in DMSO resulted in the coordination cages 
[Pd2(L)4](BF4)4 C1a-C3a, respectively, within one hour. The synthesis of the carboxy-functionalized ligand L1a and cage C1a,
22 
as well as of the amine-based ligand L3a and cage C3a were previously reported,15 while ligand L2a and cage C2a were 
synthesized for the first time following a similar procedure and characterised by NMR and mass spectrometry (Fig. S1-S5 in the 
Supplementary material). In the 1H NMR spectrum of C2a, the pyridyl proton signals (Ha-Hd) are significantly shifted downfield 
upon cage formation (Fig. S3). Additional proof for successful cage formation of C2a is given by diffusion-ordered NMR 
spectroscopy (DOSY) revealing a Dligand/ Dcomplex ratio of about 2:1 being in line with literature values.
15 High-resolution ESI–
MS analysis of C2a shows the expected isotope abundance distribution, with the most intense peaks at m/z = 405.8232, 
569.7655 and 897.1510, which can be assigned to [Pd2(L2a)4]
4+, [Pd2(L2a)4(BF4
-)] 3+ and [Pd2(L2a)4(BF4
-)2]
3+, respectively (See 














Figure 1. Scheme of the two different bioconjugation approaches applied in this study: i) direct tethering of the metallacage to the peptide 
(Approach I); or ii) initial anchoring of the ligand to the peptide, followed by metallacage self-assembly in situ (Approach II). Theoretically, both 
approaches can produce bioconjugated Pd2L4 cages tethered to four peptide units. 
 
Bioconjugation 
Initially, the direct bioconjugation of cages C1a and C2a to the protected model peptide Ac-NLEFK-Am (acetylated (Ac) 
at the N-terminal and amidated (Am) at the C-terminus) (Approach I, Fig. 1) was attempted via activation of C1a or C2a with 
DCC (N',N'-dicyclohexyl carbodiimide) and NHS (N-hydroxysuccinimide) as described in the experimental section. Subsequently, 
the peptide was added to the intermediate product solution in bicarbonate buffer (pH=9.2) and stirred for 1 h. In the case of 
the NH2 exo-functionalized cage C3a, bioconjugation was carried out by adding EDC to the mixture of model peptide and C3a in 
MES buffer (pH=4.7). 
 
Representative results for cage C1a are reported in Fig. S6 in the Supplementary material. The result from MS analysis 
shows that Approach I gives low yield of the bioconjugate product C1c (quadruply charged ion m/z = 1050.5178). Moreover, a 
variable number of peptide units were coupled to the cage. Specifically, cages tethered to either one, two or three peptide 
moieties were detected, corresponding to the most abundant peaks C1c-1 (triply charged, m/z = 727.66), C1c-2 (quadruply 
charged, m/z = 713.89; triply charged, m/z = 951.40), C1c-3 (quadruply charged, m/z = 882.17; triply charged, m/z = 1175.16), 
respectively. In the MS spectrum, the most abundant peaks were attributed to [C1c-3+DCC] species (quadruply charged, m/z = 
934.02; triply charged, m/z = 1244.84), corresponding to one DCC moiety coupled to the carboxylic acid group of the model 
peptide after formation of C1c-3. 
 
Similar results were obtained when bioconjugating cage C2c, featuring the longer linker between the cage and the COOH 
group (data not shown). In the case of cage C3a, the activating agent EDC was utilized to promote coupling to the model 
peptide but most of the peptide appeared to undergo cyclization reactions under these conditions preventing successful 
bioconjugation. 
 
In general, the obtained results show that it is difficult to both control the number of peptides coupled to the Pd2L4 cage 
and efficiently separate the mixture of different types of bioconjugated cages using Approach I. 
 
Therefore, Approach II (Fig. 1) was attempted where the carboxylic acid groups of ligands L1a or L2a were first activated via 
EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) and sulfo-NHS (N-hydroxysulfosuccinimide) treatment. Afterwards, the 
coupling reaction was accomplished by incubating the protected model peptide with 0.5% TEA for 0.5 h (pH=7). In the case of 
the NH2 exo-functionalized ligand L3a, bioconjugation was achieved by adding EDC directly to a solution of L3a and the model 
peptide in MES buffer (pH = 4.7). The chromatogram obtained to analyze the bioconjugation reaction of ligands L1a and L2a are 
depicted in Fig. S7 (panels A and C), and show almost complete conversion of the ligands into the desired products. In fact, L1b 
(L1a-peptide) and L2b (L2a-peptide) are obtained, with a yield higher than 90%. The results show no significant difference in 
yield of coupling reaction using the ligand with longer aliphatic linker. Fig. S7 (panels B and D) show the MS spectrum of the 
bioconjugate products L1b (singly charged, m/z = 997.45; doubly charged, m/z = 499.22) and L2b (singly charged, m/z = 
1025.59; doubly charged m/z = 513.32) obtained by ion trap MS. 
 
The amino-functionalized ligand L3a forms bioconjugate L3b (L3a-peptide, singly charged, m/z = 968.59; doubly charged, 
m/z = 484.80) less efficiently (singly charged, m/z = 968.59; doubly charged, m/z = 484.80) most likely due to formation of 
internal cyclization and dimerization from the model peptide (Fig. S7, panels E and F). Thus, only L1b and L2b were selected to 
achieve self-assembly of the bioconjugated cages. 
 
Subsequently, the bioconjugated cages C1c or C2c were formed in situ using a 2:1 ratio of L1b or L2b and the Pd2+ 
precursor [Pd(NCCH3)4](BF4)2 in DMSO. Representative extracted ion chromatograms and mass spectrum for the bioconjugate 
cage C2c is reported in Figure 2. Fig. S8 in the Supplementary material shows the mass spectrum of bioconjugated cage C1c. 
The results show that both the bioconjugate ligands L1b and L2b are converted into cage molecules tethered to four peptide 


















Figure 2. In situ self-assembly of the bioconjugated cage C2c with peptide Ac-NLEFK-Am analysed by MS with 75% acetonitrile and 0.1% formic 
acid infused at 50 µL/min. (A) Extracted ion signals of bioconjugated ligand L2b (green) and of bioconjugated cage C2c (red) at 10 min after self-
assembly. (B) Mass spectrum and molecular structure of the bioconjugated product C2c.
Table 1. Main peaks identified in the mass spectra of C2c and their corresponding CID fragments. The m/z values refer to the most intense 
isotopomer, since the monoisotopic peak has low intensity. No additional peaks were observed in the mass spectrum of the self-assembly 
reaction of C2c. 
 
 Reaction and  m/z Error 
CID fragment 
 
observed ions Measured Theoretical /ppm 
  




1078.1852 1078.1839 1.2 1129.48 
     
1640.11 




1437.2448 1437.2430 1.3 1129.25 
     
1641.56 
 
The identity of peaks from C1c and C2c were confirmed by comparison of the experimental and theoretical isotopic patterns, 
and by CID MS/MS analysis using high resolution MS (Table 1 and Fig. S9 for cage C2c, Table S2 and Fig. S10 for cage C1c, 
respectively). Fig. S9 shows that collision induced dissociation (CID) fragmentation of the quadruply charged precursor ion (m/z 
= 1078.19) and triply charged precursor ion (m/z = 1437.25) of bioconjugated cage C2c leads to dissociation into singly-charged 
product ions of [L2b+H]+ (m/z = 1025.52 and m/z = 1025.57, respectively). Similarly, Fig. S10 shows that CID fragmentation of 
the quadruply charged precursor ion (m/z = 1050.40) and the triply charged precursor ion (m/z = 1399.54) of bioconjugated 




With the aim of implementing supramolecular metallacages as drug delivery systems, we report the first example of 
bioconjugation of self-assembled Pd2L4 cages to the model linear peptide Ac-NLEFK-Am. The obtained results open the 
possibility of efficient bioconjugation of metallacages to peptides which could be extended to targeting moieties such as cyclic 
RGD peptides or affimers, and possibly also to antibodies. This opportunity is particularly attractive in the case of metallacages 
encapsulating anticancer drugs (e.g.: cisplatin) in order to efficiently target them to cancer cells. Two approaches of 
bioconjugation of metallocages to peptides have been attempted, both based on amide bond formation between the carboxylic 
acid (or amine) serving as exo- functionalized ligand/cage and the amine (or carboxylic acid) groups of the model peptide side 
chains. So far the best results were achieved with Approach II, where first the coupling of the peptide to the ligands 
constituting the cages was performed, followed by in-situ reconstitution of the Pd2L4 cages via self-assembly. No major 
advantages were noticed in the use of a long-linker COOH moiety for bioconjugation in both approaches. Instead, improved 
bioconjugation efficiency was observed in the case of the exo-functionalization with carboxylic acids compared to amino 
groups. In the latter case, formation of peptide cyclic by-products prevented efficient bioconjugation under the applied reaction 
conditions. Nevertheless, NH2 functionalization may still be suitable for bioconjungation of the cages with peptides of different 
sequences and with antibodies, and will certainly be considered in future studies.  
Future research in our group will focus on tethering Pd2L4 cages to targeting peptides and to investigate the activity of the 
supramolecular bioconjugates in cancer cells and tissues. 
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